Moderna Call Flow Hits 71% as Shares Retreat From High
Moderna, Inc. shares retreated from a $280.80 52-week high, while $26.0 million in options premium carried a 71% call tilt on Nov. 9. Key support sits at $253.33 and $237.65.
Topic
Topic
Moderna, Inc. shares retreated from a $280.80 52-week high, while $26.0 million in options premium carried a 71% call tilt on Nov. 9. Key support sits at $253.33 and $237.65.
GSK and Moderna settled all patent suits over Spikevax, mNEXSPIKE and mResvia, swapping cross-licenses with no payments. GSK's pa…
Moderna returned to quarterly profit with $162 million in net income, raised 2026 revenue growth guidance to 15%-25% and ended Se…
Moderna lifted its revenue outlook to 15%-25% growth after Q3 revenue of $1.3 billion beat estimates, and said it is preparing to…
Moderna beat estimates with $1.31 billion in Q3 revenue and a 38-cent profit, raising 2026 growth guidance to 15-25% as new vacci…
Moderna fell 7.4% as intismeran's Phase 3 data — a 42% cut in recurrence risk — hit via broken embargo, cooling expectations ahea…
Moderna and Merck's intismeran plus Keytruda cut melanoma recurrence or death risk by 42% over two years, yet Moderna's stock dro…
Moderna shares plunged 25% despite its melanoma vaccine with Merck cutting recurrence or death risk by 42%, as leaked data met el…
Citi has issued a sell recommendation on Moderna, arguing that revenue and profit forecasts cannot justify a share price that has…